Log in
NASDAQ:QTRX

Quanterix Stock Forecast, Price & News

$40.59
-0.28 (-0.69 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$39.44
Now: $40.59
$41.38
50-Day Range
$30.73
MA: $36.28
$46.15
52-Week Range
$10.90
Now: $40.59
$48.95
Volume136,066 shs
Average Volume205,557 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Read More
Quanterix logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400
Employees248

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.73 million
Book Value$4.59 per share

Profitability

Net Income$-40,800,000.00

Miscellaneous

Market Cap$1.15 billion
Next Earnings Date11/13/2020 (Estimated)
OptionableNot Optionable
$40.59
-0.28 (-0.69 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quanterix (NASDAQ:QTRX) Frequently Asked Questions

How has Quanterix's stock price been impacted by Coronavirus?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QTRX shares have increased by 119.3% and is now trading at $40.59.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Quanterix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quanterix
.

When is Quanterix's next earnings date?

Quanterix is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Quanterix
.

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) released its earnings results on Tuesday, August, 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.07. The company earned $13.13 million during the quarter, compared to analysts' expectations of $10.67 million. Quanterix had a negative return on equity of 35.42% and a negative net margin of 73.39%.
View Quanterix's earnings history
.

What price target have analysts set for QTRX?

3 Wall Street analysts have issued 1-year price targets for Quanterix's shares. Their forecasts range from $40.00 to $48.00. On average, they expect Quanterix's share price to reach $42.67 in the next year. This suggests a possible upside of 5.1% from the stock's current price.
View analysts' price targets for Quanterix
.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

Who are Quanterix's key executives?

Quanterix's management team includes the following people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58, Pay $1.31M)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 67, Pay $41k)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 44, Pay $501.87k)
  • Mr. John J. Fry, Gen. Counsel & Corp. Sec. (Age 59, Pay $465k)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 61)

When did Quanterix IPO?

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.19%), Foundry Partners LLC (0.07%), Cadence Capital Management LLC (0.04%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John J Fry, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix
.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix
.

Which institutional investors are buying Quanterix stock?

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Foundry Partners LLC, and Nisa Investment Advisors LLC. Company insiders that have bought Quanterix stock in the last two years include David R Walt, and John M Connolly.
View insider buying and selling activity for Quanterix
.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $40.59.

How big of a company is Quanterix?

Quanterix has a market capitalization of $1.15 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 248 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.